Results 11 to 20 of about 49,566 (218)

HBeAg mediates inflammatory functions of macrophages by TLR2 contributing to hepatic fibrosis

BMC Medicine, 2021
Background We and others have confirmed activation of macrophages plays a critical role in liver injury and fibrogenesis during HBV infection. And we have also proved HBeAg can obviously induce the production of macrophage inflammatory cytokines compared
Xiaoyu Xie, Huanran Lv, Chenxi Liu, Xiaonan Su, Zhen Yu, Shouyang Song, Hongjun Bian, Miaomiao Tian, Chengyong Qin, Jianni Qi, Qiang Zhu   +10 more
doaj   +2 more sources

Efficacy of a combination of HBV RNA and HBeAg in predicting HBeAg seroconversion in patients treated with entecavir for 144 weeks

International Journal of Infectious Diseases, 2020
Background: In some previous studies, serum hepatitis B virus RNA (HBV RNA) was proposed as an HBV viral marker during therapy. However, the dynamic change of HBV RNA, the correlation of HBV RNA with cccDNA, and the combination of HBV RNA with known HBV ...
Xiaomei Wang, Zhongfeng Wang, Xiumei Chi, Ruihong Wu, Qinglong Jin, Hongqin Xu, Xiuzhu Gao, Lei Yu, Yuping Chen, Jia Shang, Longgen Liu, Shuqin Zhang, Yongfang Jiang, Mingxiang Zhang, Qiaoxia Tong, Lunli Zhang, Youwen Tan, Anlin Ma, Shuangsuo Dang, Bin Xu, Zhenjing Jin, Jia Li, Xiaobo Li, Fengmin Lu, Junqi Niu   +24 more
doaj   +2 more sources

Is the function of the HBeAg really unknown?

Human Vaccines & Immunotherapeutics, 2019
The immune response to the hepatitis B virus (HBV) vaccine in newborns of hepatitis B e antigen (HBeAg)-positive or HBeAg-negative mothers is the subject of Huang et al. The authors report no correlation between the HBeAg status of the mothers/cord blood
David R. Milich
doaj   +2 more sources

HBeAg Seroconversion in HBeAg-Positive Chronic Hepatitis B Patients Receiving Long-Term Nucleos(t)ide Analog Treatment: A Systematic Review and Network Meta-Analysis.

PLoS ONE, 2017
BackgroundHBeAg seroconversion is an important intermediate outcome in HBeAg-positive chronic hepatitis B (CHB) patients. This study aimed to compare the effect of nucleos(t)ide analogs (NAs) on HBeAg seroconversion in treating CHB with lamivudine ...
Tongjing Xing, Hongtao Xu, Lin Cao, Maocong Ye   +3 more
doaj   +2 more sources

Hepatitis B Core-Related Antigen Level Predicts Disease Progression in the Gray Zone Hepatitis B Patients. [PDF]

J Med Virol
ABSTRACT Objectives The natural history of hepatitis B virus (HBV) infection does not always conform to the currently defined phases, and some patients who do not clearly meet established treatment criteria are classified as in the gray zone (GZ). We investigated the factors for progression of hepatitis B e antigen (HBeAg)‐negative GZ patients to ...
Suzuki T, Matsuura K, Inoue T, Kawamura H, Fujiwara K, Kataoka H, Tanaka Y.   +6 more
europepmc   +2 more sources

Taurocholic acid inhibits the response to interferon-α therapy in patients with HBeAg-positive chronic hepatitis B by impairing CD8+ T and NK cell function

Cellular & Molecular Immunology, 2021
Pegylated interferon-alpha (PegIFNα) therapy has limited effectiveness in hepatitis B e-antigen (HBeAg)-positive chronic hepatitis B (CHB) patients. However, the mechanism underlying this failure is poorly understood.
Zhen Xun, Jinpiao Lin, Qingqing Yu, Can Liu, Jin-lan Huang, Hongyan Shang, Jianhui Guo, Y. Ye, Wennan Wu, Yongbin Zeng, Songhang Wu, Siyi Xu, Tianbin Chen, J. Chen, Q. Ou   +14 more
semanticscholar   +1 more source

Mitochondrial stress in advanced fibrosis and cirrhosis associated with chronic hepatitis B, chronic hepatitis C, or nonalcoholic steatohepatitis

Hepatology, EarlyView., 2022
Adaptive mitochondrial mechanisms allow mitochondrial resilience and prevent the worsening of fibrosis, while deregulation of these mechanisms promotes the progression from no/minimal‐mild (F0‐F2) fibrosis to advanced fibrosis and cirrhosis (F3‐F4). Abstract Background and Aims Hepatitis B virus (HBV) infection causes oxidative stress (OS) and alters ...
Dimitri Loureiro, Issam Tout, Stéphanie Narguet, Cheikh Mohamed Bed, Morgane Roinard, Ahmad Sleiman, Nathalie Boyer, Nathalie Pons‐Kerjean, Corinne Castelnau, Nathalie Giuly, Dorothy Tonui, Vassili Soumelis, Jamel El Benna, Patrick Soussan, Richard Moreau, Valérie Paradis, Abdellah Mansouri, Tarik Asselah   +17 more
wiley   +1 more source

Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection

Scientific Reports, 2021
The RNA interference (RNAi) drug ARC-520 was shown to be effective in reducing serum hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HBeAg-positive patients treated with a single dose of ARC-520 and ...
S. Kadelka, H. Dahari, Stanca M. Ciupe
semanticscholar   +1 more source

Accuracy of HBeAg to identify pregnant women at risk of transmitting hepatitis B virus to their neonates: a systematic review and meta-analysis.

Lancet. Infectious Diseases (Print), 2020
BACKGROUND Prevention of mother-to-child transmission (MTCT) of hepatitis B virus (HBV) involves neonatal immunoprophylaxis, with a birth dose of hepatitis B vaccine and immune globulin, and provision of peripartum antiviral prophylaxis in highly ...
P. Boucheron, Ying Lu, Kyoko Yoshida, T. Zhao, A. Funk, F. Lunel-Fabiani, A. Guingané, E. Tuaillon, Judith van Holten, R. Chou, M. Bulterys, Y. Shimakawa   +11 more
semanticscholar   +1 more source

Viral and immune factors associated with successful treatment withdrawal in HBeAg-negative chronic hepatitis B patients

Journal of Hepatology, 2020
Background & Aims Factors associated with a successful outcome upon nucleos(t)ide analogue (NA) treatment withdrawal in HBeAg-negative chronic hepatitis B (CHB) patients have yet to be clarified.
M. García-López, S. Lens, L. Pallett, B. Testoni, S. Rodríguez‐Tajes, Z. Mariño, C. Bartrés, E. García-Pras, T. Leonel, Elena Perpiñán, J. Lozano, F. Rodríguez-Frías, G. Koutsoudakis, F. Zoulim, M. Maini, X. Forns, S. Pérez‐del‐Pulgar   +16 more
semanticscholar   +1 more source